Evidence map›Paper›PMID 32094299›Full record

ArticleCancer research2020

A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.

Hernando Lopez-Bertoni, Ivan S Kotchetkov, Nicole Mihelson, Bachchu Lal, Yuan Rui, Heather Ames, Maria Lugo-Fagundo, Hugo Guerrero-Cazares, Alfredo Quiñones-Hinojosa, Jordan J Green and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hernando Lopez-BertoniHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland. Laterra@kennedykrieger.org Lopezbertoni@kennedykrieger.org.ORCID 0000-0001-6618-1092
Ivan S KotchetkovDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6202-9528
Nicole MihelsonNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland.ORCID 0000-0001-5051-0760
Bachchu LalHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.
Yuan RuiDepartment of Biomedical Engineering, Institute for NanoBioTechnology, and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Heather AmesDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
Maria Lugo-FagundoHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.
Hugo Guerrero-CazaresDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1307-719X
Alfredo Quiñones-HinojosaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jordan J GreenDepartment of Biomedical Engineering, Institute for NanoBioTechnology, and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4176-3808
John LaterraHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland. Laterra@kennedykrieger.org Lopezbertoni@kennedykrieger.org.
Johns Hopkins University · USKennedy Krieger Institute · USMemorial Sloan Kettering Cancer Center · USNational Institute of Neurological Disorders and Stroke · USUniversity of Maryland, Baltimore · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Sleep and Circadian Dysfunction, Brain and Neurobehavioral Development in AutismP50HD103538 · NICHD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI S. Ali Fatemi, Bradley L Schlaggar · 2020 to 2026
$9.9M
Chromatin Modifications in GBM-Propagating CellsR01NS096754 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2017 to 2021
$2.2M
Gene Delivery Nanoparticles to Treat GlioblastomaR01EB016721 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2013 to 2017
$1.9M
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)R01CA195503 · NCI · MAYO CLINIC JACKSONVILLE · PI GREEN, JORDAN, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$1.9M
Brain Cancer Stem Cell Reprogramming by c-MetR01NS073611 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2012 to 2016
$1.8M
Zeiss LSM780 Confocal Microscope for a Core FacilityS10OD016374 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2013 to 2013
$584k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA195503NIBIB NIH HHS R01 EB016721NICHD NIH HHS P50 HD103538NIH HHS S10 OD016374NINDS NIH HHS R01 NS073611NINDS NIH HHS R01 NS096754
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) and other solid malignancies are heterogeneous and contain subpopulations of tumor cells that exhibit stem-like features. Our recent findings point to a dedifferentiation mechanism by which reprogramming transcription factors Oct4 and Sox2 drive the stem-like phenotype in glioblastoma, in part, by differentially regulating subsets of miRNAs. Currently, the molecular mechanisms by which reprogramming transcription factors and miRNAs coordinate cancer stem cell tumor-propagating capacity are unclear. In this study, we identified miR-486-5p as a Sox2-induced miRNA that targets the tumor suppressor genes

Indexed as

Cell SurvivalGenes, Tumor SuppressorAnimalsBcl-2-Like Protein 11Brain NeoplasmsCell DeathCell DedifferentiationCell Line, TumorCellular ReprogrammingEpigenetic RepressionFemaleForkhead Box Protein O1Gene Expression Regulation, NeoplasticGlioblastomaHeterograftsHumansBcl-2-Like Protein 11Forkhead Box Protein O1FOXO1 protein, humanMicroRNAsMIRN138 microRNA, humanMIRN23a microRNA, humanMIRN486 microRNA, humanNeoplasm ProteinsOctamer Transcription Factor-3PTEN PhosphohydrolasePTEN protein, humanSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID32094299
PMCPMC7165043
OpenAlexW3007474755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.